Ordenar

Buscar

31/12/2025 Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
Calle, C, Elez, E, Manzano, JL, Moreno-Martinez, ME, Pericay, C, Graefenhain, R, Ariznavarreta, A, Lizan, L. Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis. Journal Of Pharmaceutical Policy And Practice. 2025; 18(1)DOI:10.1080/20523211.2025.2567970. PMID:41415036. IF:(Q/D).
27/12/2025 Lipoprotein-Specific Fatty Acid Profiles in Familial Hypercholesterolemia: Associations with Cardiovascular History and Dietary Patterns
López-Yerena, A, Arroyo-Olivares, R, Santisteban, V, Muñoz-Garcia, N, Estruch, R, Mata, P, Badimon, L, Padro, T. Lipoprotein-Specific Fatty Acid Profiles in Familial Hypercholesterolemia: Associations with Cardiovascular History and Dietary Patterns. Nutrients. 2025; 18(1)DOI:10.3390/nu18010092. PMID:41515209. IF:5.000(Q1/2D).
25/12/2025 Ultrasound-Enhanced Assessment of Vitreous Status in Exudative AMD: Associations with Neovascular Phenotypes, Treatment Burden, and Functional Outcomes
Rodriguez-Vidal, C, Pandelo, LG, Martínez-Alday, N, Bande, M, Teijeiro, MJB. Ultrasound-Enhanced Assessment of Vitreous Status in Exudative AMD: Associations with Neovascular Phenotypes, Treatment Burden, and Functional Outcomes. Journal of Clinical Medicine. 2025; 15(1)DOI:10.3390/jcm15010167. PMID:41517415. IF:2.900(Q1/2D).
24/12/2025 PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease
Gifre, L, Fusaro, M, Lloret, MJ, Massó, E, Peris, P, Nogués, X, Gelpi, R, Prior-Español, A, Ara, J, Cozzolino, M, Ureña-Torres, PA, Bover, J. PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease. Journal of Clinical Medicine. 2025; 15(1)DOI:10.3390/jcm15010133. PMID:41517382. IF:2.900(Q1/2D).
23/12/2025 Characterizing Digital Communication Device Use Among Young People From 4 European Countries: Cross-Sectional Survey Study
Stamets, ML, Castaño-Vinyals, G, Viladoms, PD, Veludo, AF, Thielens, A, Martin, L, Wydaeghe, R, Aerts, S, Parazzini, M, Tognola, G, Wiart, J, Polanska, K, Popovic, M, López, MJ, Maule, M, Joseph, W, Grellier, J, Röösli, M, Guxens, M. Characterizing Digital Communication Device Use Among Young People From 4 European Countries: Cross-Sectional Survey Study. JOURNAL OF MEDICAL INTERNET RESEARCH. 2025; 27DOI:10.2196/76767. PMID:41432541. IF:6.000(Q1/1D).
23/12/2025 Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial
Rodés-Cabau, J, Nombela-Franco, L, Cruz-Gonzalez, I, Hibbert, B, Freixa, X, Masson, JB, Ibrahim, R, Estevez-Loureiro, R, Millan, X, Kass, M, Paradis, JM, Champagne, J, Salinas, P, Laffond, A, Abdel-Razek, O, Labinaz, M, Cepas-Guillen, P, Arzamendi, D, Vidal-Cales, P, Pavesi, M, Côté, M, O'Hara, G, Salaun, E. Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. CIRCULATION. 2025; 152(25)DOI:10.1161/CIRCULATIONAHA.125.077469. PMID:41139402. IF:38.600(Q1/1D).
20/12/2025 A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer
O'Byrne, K, Esteban, E, Lee, CL, Hegmane, A, Volovat, C, Lo Russo, G, Ziogas, D, Atmaca, A, Sebastian, M, Majem, M. A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. Future Oncology. 2025; 21(30)DOI:10.1080/14796694.2025.2597404. PMID:41383151. IF:2.600(Q3/6D).
19/12/2025 OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2
DeDiego, ML, López-Fernández-Sobrino, R, Pedragosa, J, López-García, D, Nogales, A, Durbán, J, Cardona, F, Llucià-Carol, L, Rivero, V, Vazquez-Utrilla, P, Sanchez-Grande, LP, Cobo, M, Lloret, L, Márquez-Kisinousky, L, Ruiz-Jaén, F, Lozano, F, Sibila, O, Faner, R, Castro, P, Domingo, C, Robles, V, Bedini, JL, Rico, V, Aguero, D, Soriano, A, Nalda, AM, Martinez, AP, Colobran, R, Soler-Palacín, P, Serra-Llovich, A, Dietl, B, Arranz, MJ, Dalmau, D, Signes-Costa, J, Gil-Carbonell, J, Todolí, J, Martínez, J, Rojo, S, Fiz-López, A, Arribas, E, Cal-Sabater, P, Bernado, D, Vogel, M, Wiemann, S, Abolhassani, H, Pan-Hammarström, Q, Pujol, A, Su, HC, Lee, D, Zhang, SY, Casanova, JL, Fernández-Cadenas, I, Pérez-Tur, J, Planas, AM. OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2. iScience. 2025; 28(12)DOI:10.1016/j.isci.2025.113966. PMID:41438061. IF:4.100(Q1/2D).